Identification of the Pathogenetic Mechanisms Underlying Squamous Cell Carcinomas
Identification of the Pathogenetic Mechanisms Underlying Squamous Cell Carcinomas of the Anogenital Tract and of the Head-neck Region for the Development of Shared Therapeutic Strategies
This is a multicentric, retrospective, and prospective biomarker study.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
This is a multicentric, retrospective, and prospective biomarker study, involving a total of 170 patients with SCC (Squamous Cell Carcinoma) of the mucosa of the anogenital tract and head-neck region, recruited from INT-NA (n=50), UPO (n=40), AOUP (n=40), and ITB (n=40). Specifically, retrospective and prospective samples will be collected and analyzed for the study of molecular and viral biomarkers. Simultaneously, fibroblastic tumor-associated cells (CAFs) will be isolated from prospective samples. Through co-cultivation with immortalized cell lines derived from anogenital and head-neck SCCs, these CAFs will enable the production of 3D organoids for use in experiments assessing the response to telomerase and deacetylase SIRT1 inhibitors, both in vitro and in preclinical models.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Maria Lina Tornesello, M.D.
- Phone Number: 08117770588
- Email: m.tornesello@istitutotumori.na.it
Study Locations
-
-
Bari
-
Bari, Bari, Italy, 70124
- Recruiting
- Istituto Tumori IRCCS Giovanni Paolo II di Bari
-
Contact:
- Oronzo Brunetti, M.D
- Email: dr.oronzo.brunetti1983@gmail.com
-
-
Napoli
-
Naples, Napoli, Italy, 80131
- Recruiting
- Istituto Nazionale Tumori | "Fondazione Pascale"
-
Contact:
- Maria Lina Tornesello, M.D.
- Phone Number: 08117770588
- Email: m.tornesello@istitutotumori.na.it
-
-
Novara
-
Novara, Novara, Italy, 28100
- Recruiting
- Università del Piemonte orientale
-
Contact:
- Marisa Gariglio, M.D.
- Email: marisa.gariglio@med.uniupo.it
-
-
Pisa
-
Pisa, Pisa, Italy, 56126
- Recruiting
- Azienda Ospedaliera Universitaria Pisana
-
Contact:
- Mauro Pistello, M.D.
- Phone Number: 050 221 3781
- Email: mauro.pistello@unipi.it
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
The study population consists of patients with a histological diagnosis of squamous cell carcinoma (SCC) of the anus, cervix, vulva, oral cavity, and oropharynx. At least 170 cases of anal SCC (n=30), cervical SCC (n=30), vulvar SCC (n=30), oral cavity SCC (n=40), and oropharyngeal SCC (n=40) will be prospectively enrolled and retrospectively analyzed.
Description
Inclusion Criteria:
Patients aged ≥ 18 years, candidates for surgical treatment for squamous cell carcinoma of the anus, uterine cervix, vulva, and head-neck region (including microinvasive and invasive carcinomas) who are capable of understanding and willing to sign the informed consent form. Prospective patients must provide written informed consent before any procedures.
Exclusion Criteria:
Patients presenting any of the following criteria are not eligible for inclusion in this study. Exclusion criteria include:
- Metastatic neoplasia
- Treatment for other oncological pathologies
- Congenital or acquired immunosuppression (HIV, organ transplant, pharmacological)
Study Plan
How is the study designed?
Design Details
- Observational Models: OTHER
- Time Perspectives: PROSPECTIVE
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Primary Endpoint
Time Frame: 30 months
|
Identify shared molecular profiles in squamous cell carcinomas (SCC) of the mucosa of the anogenital tract and head-neck region, dependent on the presence of somatic mutations (e.g., TERT promoter mutations and viral HPV sequences). |
30 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Secondary Endpoint
Time Frame: 30 months
|
Inhibition of growth in organoids obtained from tumor cells mutated in the TERT promoter or expressing viral oncogenes and SIRT1. |
30 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Maria Lina Tornesello, M.D., IRCCS I.N.T. "G. Pascale"
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Site
- Neoplasms
- Intestinal Diseases
- Neoplasms by Histologic Type
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Digestive System Diseases
- Gastrointestinal Diseases
- Colorectal Neoplasms
- Intestinal Neoplasms
- Rectal Diseases
- Head and Neck Neoplasms
- Neoplasms, Glandular and Epithelial
- Carcinoma
- Carcinoma, Squamous Cell
- Anus Diseases
- Rectal Neoplasms
- Squamous Cell Carcinoma of Head and Neck
- Anus Neoplasms
Other Study ID Numbers
Other Study ID Numbers
- PNRR-MAD-2022-12376570
- 9/23 oss (Other Identifier: IRCCS I.N.T. "G. Pascale")
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.